SI2481405T1 - Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku - Google Patents
Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti rakuInfo
- Publication number
- SI2481405T1 SI2481405T1 SI200731795A SI200731795A SI2481405T1 SI 2481405 T1 SI2481405 T1 SI 2481405T1 SI 200731795 A SI200731795 A SI 200731795A SI 200731795 A SI200731795 A SI 200731795A SI 2481405 T1 SI2481405 T1 SI 2481405T1
- Authority
- SI
- Slovenia
- Prior art keywords
- paclitaxel
- nanoparticles
- albumin
- combination
- against cancer
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229930012538 Paclitaxel Natural products 0.000 title 1
- 229960000397 bevacizumab Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 229960001592 paclitaxel Drugs 0.000 title 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/594,417 US20070166388A1 (en) | 2005-02-18 | 2006-11-06 | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP12154995.0A EP2481405B1 (en) | 2006-11-06 | 2007-11-06 | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2481405T1 true SI2481405T1 (sl) | 2016-08-31 |
Family
ID=39111840
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200731795A SI2481405T1 (sl) | 2006-11-06 | 2007-11-06 | Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku |
| SI200731475T SI2097078T1 (sl) | 2006-11-06 | 2007-11-06 | Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200731475T SI2097078T1 (sl) | 2006-11-06 | 2007-11-06 | Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070166388A1 (enExample) |
| EP (3) | EP2097078B1 (enExample) |
| JP (3) | JP5931323B2 (enExample) |
| KR (4) | KR20090087906A (enExample) |
| CN (2) | CN104940929A (enExample) |
| AU (1) | AU2007317859B2 (enExample) |
| BR (1) | BRPI0718528A2 (enExample) |
| CA (1) | CA2668607A1 (enExample) |
| CY (2) | CY1115271T1 (enExample) |
| DK (2) | DK2481405T3 (enExample) |
| ES (2) | ES2469716T3 (enExample) |
| HU (1) | HUE028472T2 (enExample) |
| IL (2) | IL198576A (enExample) |
| MX (1) | MX2009004803A (enExample) |
| NO (1) | NO343908B1 (enExample) |
| NZ (1) | NZ576856A (enExample) |
| PL (2) | PL2097078T3 (enExample) |
| PT (2) | PT2097078E (enExample) |
| RU (2) | RU2009121568A (enExample) |
| SI (2) | SI2481405T1 (enExample) |
| WO (1) | WO2008057562A1 (enExample) |
| ZA (1) | ZA200903132B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| KR100904931B1 (ko) * | 1997-06-27 | 2009-06-29 | 아브락시스 바이오사이언스, 엘엘씨 | 나노 입자 및 그의 제조 방법 |
| LT1585548T (lt) * | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ595313A (en) | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| KR101643416B1 (ko) * | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
| CA2880727C (en) | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| EP2468868A1 (en) * | 2006-06-26 | 2012-06-27 | The University Of British Columbia | Chemotherapeutic sensitizers |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| KR20090095571A (ko) * | 2006-11-01 | 2009-09-09 | 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 | 암을 검출하고 조절하기 위한 방법 |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20150002886A (ko) * | 2007-03-07 | 2015-01-07 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| EP3326630A3 (en) * | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CA2686225A1 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without tween 80 |
| ITMI20080284A1 (it) * | 2008-02-22 | 2009-08-23 | Indena Spa | Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono |
| WO2009126401A1 (en) * | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2310006A4 (en) | 2008-07-03 | 2012-04-25 | Mayo Foundation | CANCER TREATMENT |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| PT2387395E (pt) * | 2009-01-16 | 2015-02-04 | Rigel Pharmaceuticals Inc | Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático |
| CN102427728A (zh) * | 2009-03-13 | 2012-04-25 | 阿布拉科斯生物科学有限公司 | 用硫代秋水仙碱衍生物进行联合治疗 |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| MX2012000383A (es) * | 2009-07-07 | 2012-06-01 | Normoxys Inc | Método para reducir la resistencia a terapias multidroga utilizando tripirofosfato de inositol. |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| CN110227154A (zh) | 2010-02-23 | 2019-09-13 | 霍夫曼-拉罗奇有限公司 | 用于治疗卵巢癌的抗血管发生疗法 |
| PL2552438T3 (pl) | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
| BR112012024590A2 (pt) * | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| JP6257324B2 (ja) | 2010-06-04 | 2018-01-10 | アブラクシス バイオサイエンス， エルエルシー | 膵臓がんの処置方法 |
| EP3056201A1 (en) * | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| US20120121510A1 (en) * | 2010-11-11 | 2012-05-17 | Brem Rachel F | Localized therapy following breast cancer surgery |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| ES2792062T3 (es) | 2011-05-09 | 2020-11-06 | Mayo Found Medical Education & Res | Tratamientos contra el cáncer |
| BR112014010417A2 (pt) | 2011-11-01 | 2014-11-18 | Celgene Corp | Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| SMT201900502T1 (it) | 2011-12-14 | 2019-11-13 | Abraxis Bioscience Llc | Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle |
| BR112014018964A2 (pt) * | 2012-03-13 | 2020-05-12 | F. Hoffmann-La Roche Ag | Anticorpo anti-vegf e uso de um anticorpo anti-vegf |
| ES2899643T3 (es) | 2012-10-01 | 2022-03-14 | Mayo Found Medical Education & Res | Tratamientos para el cáncer |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CN109200031A (zh) * | 2013-02-11 | 2019-01-15 | 阿布拉科斯生物科学有限公司 | 治疗黑素瘤的方法 |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| WO2015134543A1 (en) * | 2014-03-05 | 2015-09-11 | Sorrento Therapeutics, Inc. | Pharmacokinetically equivalent nanoparticle compositions |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| AU2015274408A1 (en) | 2014-06-13 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating lymphomas |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| WO2016057554A1 (en) * | 2014-10-06 | 2016-04-14 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| JP6987644B2 (ja) | 2015-06-29 | 2022-01-05 | アブラクシス バイオサイエンス， エルエルシー | 類上皮細胞腫瘍を処置する方法 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| CN114796130B (zh) * | 2015-08-18 | 2023-10-20 | 梅约医学教育与研究基金会 | 载体结合剂组合物及其制备和使用方法 |
| WO2017176265A1 (en) * | 2016-04-06 | 2017-10-12 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| WO2017165439A1 (en) * | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| RU2019105550A (ru) * | 2016-08-05 | 2020-09-07 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования |
| EP3505165B1 (en) * | 2016-08-26 | 2025-11-26 | Tetsuji Okuno | Method of producing a fine nano-sized medicinal agent |
| CA3035378A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| AU2017324335A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| CN106310291A (zh) * | 2016-09-14 | 2017-01-11 | 东南大学 | 主动靶向抗肿瘤纳米药物及其制备方法和应用 |
| HRP20220375T1 (hr) | 2016-10-27 | 2022-05-13 | Celgene Quanticel Research, Inc. | Kombinirana terapija inhibitorom bromodomenskog i ekstraterminalnog proteina |
| CA3042238C (en) * | 2016-10-28 | 2021-08-10 | Nant Holdings Ip, Llc | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| IL274444B2 (en) | 2017-11-06 | 2024-06-01 | Rapt Therapeutics Inc | Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer |
| WO2019104042A1 (en) * | 2017-11-21 | 2019-05-31 | University Of Iowa Research Foundation | Synthetically lethal nanoparticles for treatment of cancers |
| WO2019126223A1 (en) * | 2017-12-19 | 2019-06-27 | Abraxis Bioscience, Llc | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
| EP4495136A3 (en) | 2018-01-26 | 2025-04-23 | The Regents of the University of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| WO2021086946A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| KR102263606B1 (ko) | 2020-02-11 | 2021-06-10 | 충북대학교 산학협력단 | 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| KR100240308B1 (ko) | 1991-03-06 | 2000-01-15 | 플레믹 크리스티안 | 인간화된단클론성항체및혼성단클론성항체 |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| AU1831395A (en) | 1994-01-14 | 1995-08-01 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| EP1071440B1 (en) | 1998-04-16 | 2007-01-03 | Eurovita A/S | Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| KR20160014775A (ko) * | 2003-05-30 | 2016-02-11 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| EP1682181A2 (en) * | 2003-09-23 | 2006-07-26 | Novartis AG | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
| US20060003931A1 (en) | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor and methods of use |
| BRPI0510915A (pt) | 2004-06-04 | 2007-11-13 | Genentech Inc | método para o tratamento da esclerose múltipla e artigo manufaturado |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| AU2006207321B2 (en) * | 2005-01-21 | 2012-09-06 | Astex Therapeutics Limited | Pharmaceutical compounds |
| NZ595313A (en) * | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| JPWO2006090928A1 (ja) * | 2005-02-28 | 2008-07-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の血管新生阻害物質との新規併用 |
| KR101643416B1 (ko) * | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
| CA2880727C (en) * | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
-
2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
-
2007
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/en active
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
-
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
-
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
-
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
-
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
-
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244390A0 (en) | Nonparticles of paclitaxel and albumin in combination with bevacizumab against cancer | |
| HRP20181217T1 (hr) | Nanočestica koja kao antikancerogeno sredstvo sadrži rapamicin i albumin | |
| EP2038041A4 (en) | THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER | |
| IL247617A0 (en) | Peptide nanoparticles and their uses | |
| IL199609A0 (en) | Antifolate agent combinations in the treatment of cancer | |
| EP2048189A4 (en) | ALUMINUM OXIDE NANOPARTICLE WITH COATED SURFACE AND RESIN COMPOSITION THEREOF | |
| ZA201008045B (en) | Nanoparticle formulations and uses thereof | |
| HUE050370T2 (hu) | Rosszindulatú daganat kezelése elektromágneses mezõ és rákellenes szerek kombinációjával | |
| ZA200902161B (en) | Antiobodies and immunoconjugates and uses therefor | |
| GB2461473B (en) | Nanoparticles and fabrication thereof | |
| IL209361A0 (en) | Combination therapy with pm00104 and another antitumor agent | |
| IL242077B (en) | Sp–1 complexes with nanoparticles and their use | |
| GB0503216D0 (en) | Nanoparticles and uses there of | |
| GB0603433D0 (en) | Nanoparticle and nanocomposite films | |
| HK1156219A (en) | Combination therapy with pm00104 and another antitumor agent |